PRESS RELEASE

Q2 2021 — Press release

Q2 2021PDF · 14 pages268 KB
News Release
FOR IMMEDIATE
Media Contacts:
RELEASE
Patrick Ryan Investor Contacts: Peter Dannenbaum
(973) 275-7075 (908) 740-1037
Melissa Moody
(215) 407-3536
Raychel Kruper
(908) 740-2107
Merck Announces Second-Quarter 2021 Financial Results
• Second-Quarter 2021 Worldwide Sales from Continuing Operations (Excluding Organon)
Were $11.4 Billion, 22% Above Second-Quarter 2020; Excluding the Impact from Foreign
Exchange, Sales Grew 19% Reflecting Ongoing Recovery from the COVID-19 Pandemic
and Strong Underlying Demand Across the Company’s Portfolio of Innovative Products:
o KEYTRUDA Sales Grew 23% to $4.2 Billion; Excluding the Impact from Foreign
Exchange, Sales Grew 20%
o GARDASIL/GARDASIL 9 Sales Grew 88% to $1.2 Billion; Excluding the Impact from
Foreign Exchange, Sales Grew 78%
o Animal Health Sales Grew 34% to $1.5 Billion; Excluding the Impact from Foreign
Exchange, Sales Grew 27%
• Second-Quarter 2021 GAAP EPS from Continuing Operations Was $0.48; Second-Quarter
2021 Non-GAAP EPS from Continuing Operations Was $1.31
• Progressed Pipeline and Secured Multiple Regulatory Approvals, Including FDA Approval of
VAXNEUVANCE, Merck’s 15-Valent Pneumococcal Conjugate Vaccine, for Adults; FDA
Approvals for Neoadjuvant/Adjuvant KEYTRUDA in Combination With Chemotherapy for
High-Risk Early-Stage Triple-Negative Breast Cancer (KEYNOTE-522) and KEYTRUDA in
Combination with Lenvima for the Treatment of Certain Patients With Advanced Endometrial
Carcinoma (KEYNOTE-775/Study 309)
• Completed the Spinoff of Organon on June 2; Received Cash Distribution of Approximately
$9 Billion
• 2021 Continuing Operations Financial Outlook:
o Expects Full-Year 2021 Sales Growth of 12% to 14%; Narrows and Raises
Estimated Full-Year 2021 Revenue Range to be Between $46.4 Billion and $47.4
Billion, Including a Positive Impact from Foreign Exchange of Less Than 2%

-- 1 of 14 --

Page 2
o Expects Full-Year 2021 GAAP EPS to be Between $4.24 and $4.34; Expects Full-
Year 2021 Non-GAAP EPS to be Between $5.47 and $5.57, Including a Positive
Impact from Foreign Exchange of Approximately 2%
KENILWORTH, N.J., July 29, 2021 – Merck (NYSE: MRK), known as MSD outside the United
States and Canada, today announced financial results for the second quarter of 2021.
“We are encouraged by the strong momentum of our underlying business led by our key
growth drivers as the impact of the pandemic on our performance lessens,” said Rob Davis,
chief executive officer and president, Merck. “We are confident that we will deliver sustained
long-term growth and value creation enabled by our strengthening discovery research engine
and by working with increased speed, urgency and agility to accelerate the delivery of our
innovations to the patients who depend on them.”
Financial Summary – Continuing Operations
The businesses that were contributed to Organon & Co. (Organon) in the spinoff are
now accounted for as discontinued operations. Financial information presented in this release
reflects Merck’s results on a continuing operations basis, which excludes Organon. Prior periods
have been recast to conform to this presentation. The Company previously filed a Form 8-K on
June 21, 2021, which included historical financial information recast to reflect Organon as
discontinued operations.
$ in millions, except EPS amounts
Second Quarter
2021 2020 Change
Change
Ex-
Exchange
Sales $11,402 $9,353 22% 19%
GAAP net income1 1,213 2,341 -48% -47%
Non-GAAP net income that excludes certain
items1,2* 3,321 2,586 28% 27%
GAAP EPS 0.48 0.92 -48% -48%
Non-GAAP EPS that excludes certain items2* 1.31 1.02 28% 27%
*Refer to table on page 11.
1 Net income attributable to Merck & Co., Inc.
2 Merck is providing certain 2021 and 2020 non-GAAP information that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results and permits investors to understand how management
assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part
using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to,
information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this
release.

-- 2 of 14 --

Page 3
GAAP (generally accepted accounting principles) earnings per share assuming dilution
(EPS) was $0.48 for the second quarter of 2021. GAAP EPS for the second quarter of 2021
includes a $1.7 billion charge for the acquisition of Pandion Therapeutics, Inc. (Pandion). Non-
GAAP EPS of $1.31 for the second quarter of 2021 excludes acquisition- and divestiture-related
costs, restructuring costs, income and losses from investments in equity securities, the charge
related to Pandion and certain other items. Year-to-date results can be found in the attached
tables.
Oncology Program Highlights
Merck continued to advance development programs across its oncology portfolio,
anticipating greater than 90 potential new indications by 2028, including notable progress for
KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy; Lynparza (olaparib), an oral
poly ADP ribose polymerase (PARP) inhibitor, being co-developed and co-commercialized with
AstraZeneca; and Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor,
being co-developed and co-commercialized with Eisai Co., Ltd. (Eisai).
• Merck announced the following regulatory milestones:
o U.S. Food and Drug Administration (FDA) approval of KEYTRUDA in combination with
chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single-
agent (adjuvant) treatment after surgery in high-risk early-stage triple-negative breast
cancer (TNBC) based on results from the pivotal Phase 3 KEYNOTE-522 trial. These
results were presented during a European Society for Medical Oncology Virtual Plenary
session on July 15.
o FDA approval of KEYTRUDA in combination with trastuzumab and chemotherapy for the
first-line treatment of patients with locally advanced unresectable or metastatic human
epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction
(GEJ) adenocarcinoma based on results from the ongoing Phase 3 KEYNOTE-811 trial.
This is the first time an anti-PD-1 therapy has been approved in combination with anti-
HER2 therapy and chemotherapy as a first-line treatment for these patients. This
accelerated approval is contingent upon verification of clinical benefit in confirmatory
trials.
o FDA approval of KEYTRUDA as monotherapy for the treatment of patients with locally
advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or
radiation. This approval was based on results from the Phase 2 KEYNOTE-629 trial.

-- 3 of 14 --

Page 4
o FDA approval of KEYTRUDA in combination with Lenvima for the treatment of certain
patients with advanced endometrial carcinoma that is not microsatellite instability-high
(MSI-H) or mismatch repair deficient (dMMR), who have disease progression following
prior systemic therapy in any setting and are not candidates for curative surgery or
radiation. The approval was based on results from the confirmatory pivotal Phase 3
KEYNOTE-775/Study 309 trial.
o FDA priority review for KEYTRUDA in combination with Lenvima for the first-line
treatment of patients with advanced renal cell carcinoma (RCC) based on results from
the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307). The Prescription Drug
User Fee Act (PDUFA) or target action date is Aug. 26.
o The FDA Oncologic Drugs Advisory Committee voted against maintaining accelerated
approval of KEYTRUDA for the third-line treatment of certain patients with gastric
cancer. Merck announced a voluntary withdrawal of the accelerated approval indication
for KEYTRUDA for the treatment of patients with recurrent locally advanced or
metastatic gastric or GEJ adenocarcinoma with disease progression on or after
platinum-containing chemotherapy and at least one other prior line of therapy. As agreed
with the FDA, Merck will initiate the withdrawal in Jan. 2022.
o European Commission (EC) approval of KEYTRUDA in combination with platinum- and
fluoropyrimidine-based chemotherapy for the first-line treatment of certain patients with
locally advanced unresectable or metastatic carcinoma of the esophagus or HER2-
negative GEJ adenocarcinoma in adults whose tumors express PD-L1 (CPS>10), based
on the Phase 3 KEYNOTE-590 trial.
o Chinese National Medical Products Administration approval of Lynparza as monotherapy
for the treatment of adult patients with germline or somatic BRCA-mutated metastatic
castration-resistant prostate cancer who have progressed following prior treatment that
included a new hormonal agent (abiraterone, enzalutamide), based on data from the
Phase 3 PROfound trial.
• Merck provided additional data presentations including:
o Positive top-line overall survival (OS) results for the Phase 3 KEYNOTE-355 study
evaluating KEYTRUDA in combination with chemotherapy in patients with untreated
metastatic triple-negative breast cancer whose tumors expressed PD-L1 (CPS>10).
Data will be submitted to global health authorities and will be presented at an upcoming
medical meeting.

-- 4 of 14 --

Page 5
o Results from the pivotal Phase 3 KEYNOTE-564 trial for the adjuvant treatment of
certain patients with RCC at the 2021 American Society of Clinical Oncology (ASCO)
Annual Meeting. In the study, KEYTRUDA given after surgery demonstrated a
statistically significant and clinically meaningful reduction in the risk of disease
recurrence or death compared to placebo. Results are being submitted to global
regulatory authorities and the trial will continue to evaluate OS, a key secondary
endpoint.
o Results from the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA in
combination with chemotherapy with or without bevacizumab, confirming the trial met its
dual primary endpoints of OS and progression-free survival (PFS) in the first-line
treatment of patients with persistent, recurrent or metastatic cervical cancer regardless
of PD-L1 status. Results will be presented at an upcoming medical meeting and will be
submitted to regulatory authorities.
o Initial results presented by Merck and AstraZeneca from the Phase 3 OlympiA trial at the
2021 ASCO Annual Meeting, in which Lynparza demonstrated a statistically significant
improvement in its primary endpoint of invasive disease-free survival versus placebo
in the adjuvant treatment of patients with germline BRCA1/2 mutations and HER2-
negative early breast cancer. Results will be submitted to global regulatory authorities
and the trial will continue to assess OS as a secondary endpoint.
Vaccines Highlights
• Merck announced the FDA approval of VAXNEUVANCE (15-valent Pneumococcal
Conjugate Vaccine) for active immunization for the prevention of invasive disease caused
by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F,
23F and 33F in adults 18 years of age and older.
• Merck presented new data from the pivotal Phase 3 PNEU-AGE study of VAXNEUVANCE
compared with a 13-valent pneumococcal conjugate vaccine in adults 50 years of age and
older at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
2021.
• Merck announced VAXNEUVANCE met its primary immunogenicity and safety endpoints in
two trials from its Phase 3 pediatric clinical program. Plans are on track for submission of a
supplemental regulatory licensure application to the FDA for use in children before the end
of the year.

-- 5 of 14 --

Page 6
HIV Highlight
• Merck announced results from an ongoing Phase 2a clinical trial evaluating the safety,
tolerability and pharmacokinetics of six monthly oral doses, over 24 weeks, of islatravir, the
company’s investigational nucleoside reverse transcriptase translocation inhibitor, versus
placebo for pre-exposure prophylaxis (PrEP) of HIV-1 infection in adults at low risk of
contracting HIV-1. These data, which support the safety profile of an oral islatravir PrEP
regimen through 24 weeks versus placebo, were shared as a late-breaking oral presentation
during the virtual 11th International AIDS Society Conference on HIV Science.
Other Highlights
• The EC granted marketing authorization in the European Union for Verquvo (vericiguat) for
the treatment of symptomatic chronic heart failure in adult patients with reduced ejection
fraction who are stabilized after a recent decompensation event requiring intravenous
therapy. Verquvo is being jointly developed by Merck and Bayer AG.
• BRIDION (sugammadex) Injection 100 mg/mL was approved by the FDA for the reversal of
neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in
pediatric patients aged 2 years and older undergoing surgery.
• The FDA has informed Merck of its decision to extend the goal date for the company’s New
Drug Application for gefapixant, an investigational, orally administered, selective P2X3
receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic
cough in adults, to provide time for a full review of the submission. The extended PDUFA
action date is March 21, 2022.
COVID-19 Highlights
• In April, Merck and Ridgeback Biotherapeutics LP announced top-line data from the Phase
2 portion of the Phase 2/3 trials studying molnupiravir (MK-4482), which showed that it
inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent
of COVID-19. Data were presented at ECCMID in July. Molnupiravir is now being evaluated
in a Phase 3 clinical trial, the MOVe-OUT study, for the treatment of non-hospitalized
patients with laboratory-confirmed COVID-19 and at least one risk factor associated with
poor disease outcomes.
• In April, Merck announced that the company entered into non-exclusive voluntary licensing
agreements for molnupiravir with established Indian generic manufacturers. Merck entered
into these agreements to accelerate availability of molnupiravir in India and in other low- and

-- 6 of 14 --

Page 7
middle-income countries following approvals or emergency authorization by local regulatory
agencies.
• In June, Merck announced it entered into a procurement agreement with the United States
government for molnupiravir.
Second-Quarter Revenue Performance
The following table reflects sales of the company’s top pharmaceutical products, as well
as sales of Animal Health products.
$ in millions Second Quarter
2021 2020 Change
Change Ex-
Exchange
Total Sales $11,402 $9,353 22% 19%
Pharmaceutical 9,980 8,178 22% 18%
KEYTRUDA 4,176 3,388 23% 20%
JANUVIA / JANUMET 1,261 1,344 -6% -10%
GARDASIL / GARDASIL 9 1,234 656 88% 78%
PROQUAD, M-M-R II and
VARIVAX 516 378 36% 35%
BRIDION 387 224 72% 67%
Lynparza*
ROTATEQ
248
208
178
168
39%
23%
34%
19%
SIMPONI 202 191 5% -3%
ISENTRESS / ISENTRESS HD
Lenvima*
192
181
196
151
-2%
19%
-5%
15%
Animal Health 1,472 1,101 34% 27%
Livestock 820 647 27% 20%
Companion Animals 651 453 44% 38%
Other Revenues** (50) 74 -167% -1%
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and
commercialization costs.
**Other revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including
revenue-hedging activities. The revenue-hedging activities resulted in negative revenue in the second quarter of 2021.
Pharmaceutical Revenue
Second-quarter pharmaceutical sales increased 22% to $10.0 billion. Excluding the
favorable effect of foreign exchange, sales grew by 18%, reflecting ongoing recovery from the
COVID-19 pandemic and strong underlying demand. The COVID-19 pandemic unfavorably
affected sales in the second quarter of 2021 but to a lesser extent than in the second quarter of
2020. The estimated net favorable benefit of the ongoing COVID-19 pandemic recovery to year-
over-year sales growth was approximately $900 million.
Growth in oncology was largely driven by higher sales of KEYTRUDA, which rose 23%
to $4.2 billion in the quarter. Global sales growth of KEYTRUDA reflects continued strong

-- 7 of 14 --

Page 8
momentum from the non-small-cell lung cancer indications as well as continued uptake in other
indications, including adjuvant melanoma, RCC, bladder, head and neck squamous cell
carcinoma and MSI-H cancers. Also contributing to higher sales in oncology was a 39% rise in
Lynparza alliance revenue, reflecting continued uptake in approved indications in the United
States, Europe and China, as well as a 19% increase in Lenvima alliance revenue, driven
primarily by higher demand in China.
Growth in vaccines for the second quarter was primarily driven by higher combined sales
of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine,
Recombinant] and GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant).
Second-quarter 2021 GARDASIL/GARDASIL 9 sales rebounded to $1.2 billion, growing 88%,
primarily due to the ongoing COVID-19 pandemic recovery and strong underlying demand in the
United States, as well as continued market uptake in certain ex-U.S. markets, including China,
which also benefitted from increased supply.
Combined sales of pediatric vaccines VARIVAX (Varicella Virus Vaccine Live), a vaccine
to help prevent chickenpox; PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine
Live), a combination vaccine to help protect against measles, mumps, rubella and varicella; and
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help prevent measles,
mumps and rubella, for second-quarter 2021 rose 36% to $516 million driven primarily by the
ongoing market recovery from the COVID-19 pandemic in the United States.
Growth in hospital acute care reflects higher demand globally for BRIDION
(sugammadex) Injection 100 mg/mL, a medicine for the reversal of neuromuscular blockade
induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients aged 2
years and older undergoing surgery, which rose 72% to $387 million attributable in part to the
ongoing COVID-19 pandemic recovery; and the continued uptake of PREVYMIS (letermovir), a
medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult
CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant. Growth in
hospital acute care was partially offset by the suspension of sales of ZERBAXA (ceftolozane
and tazobactam) for injection, a combination cephalosporin antibacterial and beta-lactamase
inhibitor for the treatment of adults with certain bacterial infections, following a product recall in
the fourth quarter of 2020.
Sales of JANUVIA (sitagliptin) and JANUMET (sitagliptin and metformin HCI) decreased
6% in the quarter to $1.3 billion reflecting continued pricing pressure in the United States,
partially offset by higher demand in certain international markets.

-- 8 of 14 --

Page 9
Animal Health Revenue
Animal Health sales totaled $1.5 billion for the second quarter of 2021, an increase of
34% compared with the second quarter of 2020. Excluding the favorable effect from foreign
exchange, Animal Health sales grew 27%. Sales growth reflects higher demand globally for
companion animal products, driven by companion animal vaccines, as well as growth in
parasiticide lines of products, including BRAVECTO (fluralaner). Sales growth in livestock
products reflects higher demand for ruminant, swine and poultry products, as well as higher
demand globally for Animal Health Intelligence products. The COVID-19 pandemic unfavorably
affected Animal Health sales by approximately $100 million in the second quarter of 2020 but
had no impact in the second quarter of 2021.
Second-Quarter Expense, EPS and Related Information
The tables below present selected expense information.
$ in millions
Second-Quarter 2021 GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss from
Investments
in Equity
Securities
Certain
Other
Items
Non-
GAAP2
Cost of sales $3,104 $345 $38 $- $37 $2,684
Selling, general and
administrative 2,281 25 2 - - 2,254
Research and
development 4,321 16 6 - 1,765 2,534
Restructuring costs 82 - 82 - - -
Other (income)
expense, net (103) 117 - (258) - 38
Second-Quarter 2020
Cost of sales $2,747 $580 $25 $- $- $2,142
Selling, general and
administrative 2,085 44 11 - - 2,030
Research and
development 2,085 (63) 31 - - 2,117
Restructuring costs 82 - 82 - - -
Other (income)
expense, net (387) 63 - (511) (16) 77
GAAP Expense, EPS and Related Information
3 Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a
result of acquisitions, intangible asset impairment charges and expense or income related to changes in the estimated fair value
measurement of liabilities for contingent consideration. Also includes integration, transaction and certain other costs related to
acquisitions and divestitures.

-- 9 of 14 --

Page 10
Gross margin was 72.8% for the second quarter of 2021 compared to 70.6% for the
second quarter of 2020. The increase reflects lower acquisition- and divestiture-related costs
and favorable product mix, partially offset by the unfavorable effects of foreign exchange, pricing
pressure and higher manufacturing costs.
Selling, general and administrative expenses were $2.3 billion in the second quarter of
2021, an increase of 9% compared to the second quarter of 2020. The increase primarily
reflects higher promotion and administrative costs, as well as the unfavorable effects of foreign
exchange.
Research and development expenses were $4.3 billion in the second quarter of 2021
compared with $2.1 billion in the second quarter of 2020. The increase was primarily driven by a
$1.7 billion charge for the acquisition of Pandion, as well as higher expenses related to clinical
development, and increased investment in discovery research and early drug development.
Other (income) expense, net, was $103 million of income in the second quarter of 2021
compared to $387 million of income in the second quarter of 2020, primarily reflecting lower
income from investments in equity securities in 2021 compared with 2020.
The effective income tax rate of 29.3% for the second quarter of 2021 reflects no tax
benefit recognized on the Pandion acquisition charge.
GAAP EPS was $0.48 for the second quarter of 2021 compared with $0.92 for the
second quarter of 2020.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 76.5% for the second quarter of 2021 compared to 77.1%
for the second quarter of 2020. The decrease in non-GAAP gross margin reflects the
unfavorable effects of foreign exchange, pricing pressure and higher manufacturing costs,
partially offset by favorable product mix.
Non-GAAP selling, general and administrative expenses were $2.3 billion in the second
quarter of 2021, an increase of 11% compared to the second quarter of 2020. The increase
primarily reflects higher promotion and administrative costs, as well as the unfavorable effects of
foreign exchange.
Non-GAAP R&D expenses were $2.5 billion in the second quarter of 2021, a 20%
increase compared to the second quarter of 2020. The increase primarily reflects higher
expenses related to clinical development, as well as increased investment in discovery research
and early drug development.

-- 10 of 14 --

Page 11
Non-GAAP other (income) expense, net, was $38 million of expense in the second
quarter of 2021 compared to $77 million of expense in the second quarter of 2020.
The non-GAAP effective income tax rate was 14.6% for the second quarter of 2021.
Non-GAAP EPS was $1.31 for the second quarter of 2021 compared with $1.02 for the
second quarter of 2020.
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that
follows.
$ in millions, except EPS amounts Second Quarter
2021 2020
EPS
GAAP EPS $0.48 $0.92
Difference 0.83 0.10
Non-GAAP EPS that excludes items listed below2 $1.31 $1.02
Net Income
GAAP net income1 $1,213 $2,341
Difference 2,108 245
Non-GAAP net income that excludes items listed below1,2 $3,321 $2,586
Decrease (Increase) in Net Income Due to Excluded Items:
Acquisition- and divestiture-related costs3 $503 $624
Restructuring costs 128 149
(Income) loss from investments in equity securities (258) (511)
Charge for the acquisition of Pandion 1,704 -
Charge for the discontinuation of COVID-19 development programs 37 -
Other 61 (16)
Net decrease (increase) in income before taxes 2,175 246
Income tax (benefit) expense4 (67) (1)
Decrease (increase) in net income $2,108 $245
Financial Outlook
Merck continues to experience strong global underlying demand across its business.
Consequently, at mid-July 2021 exchange rates, Merck now expects sales growth of 12% to
14% in 2021 with full-year 2021 revenue estimated to be between $46.4 billion and $47.4 billion,
including a positive impact from foreign exchange of less than 2%.
Merck continues to believe that global health systems and patients have largely adapted
to the impacts of COVID-19 disease, and that while certain negative effects will persist, the
trend will continue to improve. Merck now estimates that the pandemic will have a net
4 Includes the estimated tax impact on the reconciling items. In addition, the amount for full-year 2021 includes a $207 million net tax
benefit related to the settlement of certain federal income tax matters.

-- 11 of 14 --

Page 12
unfavorable impact to 2021 revenues of less than 3%, all of which relates to the pharmaceutical
segment.
Merck expects full-year 2021 GAAP EPS to be between $4.24 and $4.34.
Merck expects full-year 2021 non-GAAP EPS to be between $5.47 and $5.57, including
a positive impact from foreign exchange of approximately 2%. The non-GAAP range excludes
acquisition- and divestiture-related costs, costs related to restructuring programs, income and
losses from investments in equity securities and certain other items.
For full-year 2021, Merck continues to expect the pandemic will have a negligible impact
on operating expenses, as spending on the development of its COVID-19 antiviral program is
expected to offset the favorable impact of lower spending in other areas due to the COVID-19
pandemic.
Neither the sales nor the EPS guidance ranges provided above include the impact of the
potential launch of Merck’s COVID-19 antiviral drug candidate, molnupiravir.
The following table summarizes the company’s full-year 2021 financial guidance.
GAAP Non-GAAP2
Revenue $46.4 to $47.4 billion $46.4 to $47.4 billion*
Operating
expenses
Lower than 2020 by a
mid-single digit rate
Higher than 2020 by a
high-single digit rate
Effective tax rate 14.5% to 15.5% 14.5% to 15.5%
EPS** $4.24 to $4.34 $5.47 to $5.57
*The company does not have any non-GAAP adjustments to revenue.
**EPS guidance for 2021 assumes a share count (assuming dilution) of approximately 2.53 billion shares.
A reconciliation of anticipated 2021 GAAP EPS to non-GAAP EPS and the items
excluded from non-GAAP EPS are provided in the table below.
$ in millions, except EPS amounts Full-Year 2021
GAAP EPS $4.24 to $4.34
Difference $1.23
Non-GAAP EPS that excludes items listed below2 $5.47 to $5.57
Acquisition- and divestiture-related costs
Restructuring costs
(Income) loss from investments in equity securities
$2,100
700
(1,200)
Charge for the discontinuation of COVID-19 development programs 225
Charge for the acquisition of Pandion 1,704
Other 61
Net decrease (increase) in income before taxes 3,590
Income tax (benefit) expense4 (475)
Decrease (increase) in net income $3,115

-- 12 of 14 --

Page 13
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the call
today at 8:00 a.m. EDT on Merck’s website at https://investors.merck.com/events-and-
presentations/default.aspx. Institutional investors and analysts can participate in the call by
dialing (833) 353-0277 or (469) 886-1947 and using ID code number 5951886. Members of the
media are invited to monitor the call by dialing (833) 353-0277 or (469) 886-1947 and using ID
code number 5951886. Journalists who wish to ask questions are requested to contact a
member of Merck’s Media Relations team at the conclusion of the call.
About Merck
For 130 years, Merck, known as MSD outside of the United States and Canada, has
been inventing for life, bringing forward medicines and vaccines for many of the world’s most
challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our
commitment to patients and population health by increasing access to health care through far-
reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of
research to prevent and treat diseases that threaten people and animals – including cancer,
infectious diseases such as HIV and Ebola and emerging animal diseases – as we aspire to be
the premier research-intensive biopharmaceutical company in the world. For more information,
visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline products that the products
will receive the necessary regulatory approvals or that they will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the

-- 13 of 14 --

Page 14
impact of pharmaceutical industry regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial instability of international economies
and sovereign risk; dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to litigation, including patent litigation,
and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with
the Securities and Exchange Commission (SEC) available at the SEC’s Internet site
(www.sec.gov).
# # #

-- 14 of 14 --